Pre-specified subgroup analyses of a placebo-controlled phase III trial (TEMSO) of oral teriflunomide in relapsing multiple sclerosis.
about
Teriflunomide for multiple sclerosisTeriflunomide for multiple sclerosisTherapeutic Approach to the Management of Pediatric Demyelinating Disease: Multiple Sclerosis and Acute Disseminated Encephalomyelitis.Natalizumab: a review of its use in the management of relapsing-remitting multiple sclerosis.Treating multiple sclerosis with monoclonal antibodies: a 2013 update.No evidence of disease activity: indirect comparisons of oral therapies for the treatment of relapsing-remitting multiple sclerosis.Role of oral teriflunomide in the management of multiple sclerosis.Hospitalization rates and discharge status in multiple sclerosisTeriflunomide in relapsing multiple sclerosis: therapeutic utilityTeriflunomide: a review of its use in relapsing multiple sclerosis.Management of disease-modifying treatments in neurological autoimmune diseases of the central nervous system.Teriflunomide: a novel oral treatment for relapsing multiple sclerosis.Teriflunomide for the treatment of relapsing-remitting multiple sclerosis.Leflunomide and teriflunomide: altering the metabolism of pyrimidines for the treatment of autoimmune diseases.Intervening to reduce the risk of future disability from multiple sclerosis: are we there yet?Teriflunomide for multiple sclerosis in real-world setting.Teriflunomide in multiple sclerosis: an update.The influence of patient demographics, disease characteristics and treatment on brain volume loss in Trial Assessing Injectable Interferon vs FTY720 Oral in Relapsing-Remitting Multiple Sclerosis (TRANSFORMS), a phase 3 study of fingolimod in multipSubgroups of multiple sclerosis patients with larger treatment benefits: a meta-analysis of randomized trials.Teriflunomide attenuates immunopathological changes in the dark agouti rat model of experimental autoimmune encephalomyelitis.Clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: subgroup analyses of the DEFINE study.Meta-analysis of the Age-Dependent Efficacy of Multiple Sclerosis Treatments.The tension between early diagnosis and misdiagnosis of multiple sclerosis.The neuroprotective effect of mesenchymal stem cells on an experimentally induced model for multiple sclerosis in mice.Clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: subgroup analyses of the CONFIRM study.
P2860
Q24186016-1817C7C2-5C91-4FAC-ADDA-D149666EB0F5Q24202177-A509C2B8-B7B5-471F-949C-3655A03A7C35Q30354658-A6D86C59-8FD6-478F-80E6-2F66EDAF68FAQ30659100-3C94819B-E72C-4D24-8A9D-0F667CE119ECQ34330211-68C10C5A-00A3-45E7-8621-6D35AB00A52EQ34577661-706DBA30-8AC6-451D-A3DF-5406C59B38F6Q36803649-16A8FE48-7A31-4AE0-9BB3-ABD77221483FQ36882707-BADD1E97-D50F-46C2-9019-D1EC9BDDFA08Q37117605-30A022CC-7638-4DCA-942A-AFA62200EF8DQ38160410-D87E1B0B-2780-4421-9635-30D881260E4EQ38172961-CA4E4D34-F261-4BA6-9B7A-F63B8A8EE76AQ38205268-274C04B3-E850-47DB-B977-C615C8CC5909Q38289353-26618AE0-2427-45E7-A312-48186A45ABFBQ38364965-989A953D-E10B-4C20-AA21-E47860C9D8D4Q38777286-B5143B9E-4129-4883-97CC-940DCA8DD3AFQ38891855-8D0B0BD6-1276-4CE6-BDCC-DAA42D0E4D0AQ39114065-A0087850-15CB-42DB-8270-CEE5A5B1E60FQ39195628-3EE1AA7E-B941-45A1-92BC-A6D14DBAEE1FQ41197212-ED81E52F-20EB-4CE3-A2F4-1E4FFE16A05EQ41877062-0A882C4E-F6F0-45D8-ADD6-2D03F590663EQ46760321-DFE75CE8-11B9-4DC0-94ED-0128BFEAF4A4Q47200732-B8C8E16C-0EAC-4181-B369-8304934C5A44Q47800390-FE3AE230-C916-44EB-8DD9-13F4D9A74164Q48359339-08A5FB69-1332-4C5D-8111-D29DF1A0ED35Q53326795-390878E9-14F8-41B5-A8CD-AF3DDAE23F31
P2860
Pre-specified subgroup analyses of a placebo-controlled phase III trial (TEMSO) of oral teriflunomide in relapsing multiple sclerosis.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Pre-specified subgroup analyse ...... relapsing multiple sclerosis.
@ast
Pre-specified subgroup analyse ...... relapsing multiple sclerosis.
@en
type
label
Pre-specified subgroup analyse ...... relapsing multiple sclerosis.
@ast
Pre-specified subgroup analyse ...... relapsing multiple sclerosis.
@en
prefLabel
Pre-specified subgroup analyse ...... relapsing multiple sclerosis.
@ast
Pre-specified subgroup analyse ...... relapsing multiple sclerosis.
@en
P2093
P2860
P921
P356
P1476
Pre-specified subgroup analyse ...... relapsing multiple sclerosis.
@en
P2093
Aaron E Miller
Christian Confavreux
Jerry S Wolinsky
Laura D'Castro
Mark S Freedman
Paul O'Connor
Philippe Truffinet
Teriflunomide Multiple Sclerosis Trial Group
Tomas P Olsson
P2860
P304
P356
10.1177/1352458512450354
P577
2012-06-21T00:00:00Z